RELIEF THERAPEUTICS Holding SA (SIX:RLF) announces the report of its Ordinary General Meeting 2020

17 June 2020

Geneva (Switzerland), RELIEF THERAPEUTICS Holding SA (SIX:RLF) (“Relief” or the “Company“) announces that the Ordinary General Meeting of Shareholders of Relief (the “OGM“) originally scheduled for June 19, 2020, must be postponed due to the lack of a formal requirement in the procedure for publishing the invitation to the 2020 OGM.

The new 2020 OGM date is now scheduled for July, 17, 2020. The agenda and the proposals of the Company’s board of directors remain unchanged and are available on the Company’s website (https://relieftherapeutics.com/key-information/). The new invitation will be sent to shareholders and formally published in due time in the Swiss Official Gazette of Commerce (SOGC).

As a result of the exceptional circumstances due to the COVID-19 (Coronavirus) pandemic, this new 2020 OGM will still need to be held in accordance with the requirements of the Ordinance of the Swiss Federal Council regarding measures on combatting the Coronavirus, in particular without the personal attendance of Relief’s shareholders.

The Company expresses its deepest apologies and thanks its shareholders for their understanding and support.

About RELIEF THERAPEUTICS Holding SA

RELIEF THERAPEUTICS Holding SA is a clinical stage biotechnology company with a portfolio of drug candidates derived from natural human origins. Its most promising drug candidate is Aviptadil, alias vasoactive intestinal peptide, for the treatment of Acute Respiratory Distress Syndrome (ARDS) and pulmonary sarcoidosis. With the support of its American partner NeuroRx, RELIEF THERAPEUTICS Holding SA is testing Aviptadil in two phase II/III trials on COVID-induced ARDS19 (NCT04311697 and NCT04360096). Aviptadil development in pulmonary sarcoidosis will focus on chronic sarcoidosis, an orphan disease market.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the symbol RLF.

For further information, please visit the Company’s website at www.relieftherapeutics.com or at This email address is being protected from spambots. You need JavaScript enabled to view it., and for investor relations at: This email address is being protected from spambots. You need JavaScript enabled to view it.,

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Archive